Thyrotropin Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Thyrotropin Alfa: From Thyroid Cancer Follow-Up to Migraine Disorder
One-Sentence Summary
Thyrotropin alfa is a recombinant human TSH used clinically as a diagnostic aid in thyroid cancer follow-up; detailed original-indication and mechanism-of-action data are not present in this evidence pack. The TxGNN model predicts it may be effective for Migraine Disorder with a 99.98% score, but zero clinical trials and zero publications currently support this direction — it is a pure computational hypothesis with no mechanistic rationale identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Thyroid cancer follow-up (diagnostic aid) — based on general clinical knowledge; not present in this evidence pack (0 Finland licenses on record) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.98% (model rank 368) |
| Evidence Level | L5 |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for thyrotropin alfa in this evidence pack (flagged as a High-severity data gap). What is generally known is that thyrotropin alfa is recombinant human thyroid-stimulating hormone (TSH), acting as a TSH-receptor agonist that stimulates thyroid follicular cells to take up iodine and secrete thyroglobulin/T3/T4 — a mechanism used clinically to support radioiodine imaging and thyroglobulin testing in thyroid cancer follow-up.
There is no established or hypothesized biological pathway connecting TSH-receptor signaling to migraine pathophysiology. The repurposing rationale supplied with this candidate explicitly states that no mechanistic link exists and no clinical or literature evidence supports the association — the high TxGNN score is a model output only, unsupported by any corroborating data source queried (ClinicalTrials.gov, ICTRP, PubMed all returned zero hits for this drug-disease pair).
Given the complete absence of supporting evidence and the lack of a plausible mechanism, this prediction should be treated strictly as an unvalidated computational hypothesis, not a clinically actionable signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Thyrotropin alfa is not marketed in Finland — 0 authorizations are on record in this evidence pack, so no product/dosage-form table can be produced.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA package-insert warnings/contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any S1 safety screening can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (migraine disorder) has no clinical trials, no literature, and no identified mechanistic link — it meets only L5 (model prediction only). None of the other 9 candidates in this evidence pack fare better: most are equally evidence-free (L5), and the one candidate reaching L3/S1 (hyperthyroidism) is mechanistically contradictory, since a TSH-receptor agonist would be expected to worsen rather than treat hyperthyroidism.
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) — currently blocking (DG001)
- Verified mechanism-of-action data from DrugBank (DG002)
- A mechanistic hypothesis linking TSH-receptor signaling to migraine pathophysiology, followed by preclinical validation, before any clinical evidence-gathering is warranted
- Re-screening of lower-ranked candidates once MOA data is available, to check for direction-consistent (not contradictory) mechanistic fits
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.